X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2657) 2657
Publication (222) 222
Book Review (44) 44
Newsletter (44) 44
Magazine Article (17) 17
Book Chapter (7) 7
Conference Proceeding (3) 3
Data Set (2) 2
Dissertation (1) 1
Presentation (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
alendronate (1821) 1821
humans (1411) 1411
osteoporosis (1262) 1262
female (1231) 1231
index medicus (1215) 1215
animals (1115) 1115
alendronate - pharmacology (845) 845
bisphosphonates (820) 820
male (694) 694
pharmacology & pharmacy (690) 690
bone density - drug effects (657) 657
bone density conservation agents - pharmacology (632) 632
endocrinology & metabolism (605) 605
rats (579) 579
diphosphonates - pharmacology (555) 555
middle aged (513) 513
aged (493) 493
postmenopausal women (476) 476
alendronate - therapeutic use (428) 428
bone density conservation agents - therapeutic use (425) 425
osteoporosis - drug therapy (414) 414
postmenopausal osteoporosis (364) 364
osteoporosis, postmenopausal - drug therapy (361) 361
fractures (360) 360
orthopedics (356) 356
mice (339) 339
bisphosphonate (338) 338
women (335) 335
bones (321) 321
diphosphonates - therapeutic use (319) 319
in-vitro (307) 307
bone density (296) 296
bone and bones - drug effects (291) 291
bone-mineral density (268) 268
zoledronic acid (266) 266
bone (264) 264
density (264) 264
alendronate - administration & dosage (262) 262
risedronate (255) 255
bone remodeling - drug effects (254) 254
drug therapy (248) 248
analysis (240) 240
rats, sprague-dawley (240) 240
bone density conservation agents - administration & dosage (232) 232
ovariectomy (224) 224
therapy (223) 223
risk (222) 222
bone mineral density (215) 215
osteoclasts - drug effects (208) 208
dose-response relationship, drug (207) 207
medicine & public health (207) 207
time factors (205) 205
vertebral fractures (203) 203
resorption (196) 196
mineral density (195) 195
risk factors (193) 193
aged, 80 and over (190) 190
diphosphonates - administration & dosage (186) 186
adult (185) 185
research (183) 183
osteogenesis - drug effects (182) 182
etidronic acid - analogs & derivatives (181) 181
prevention (180) 180
disease models, animal (170) 170
bone density conservation agents - adverse effects (168) 168
treatment outcome (165) 165
bone and bones - metabolism (158) 158
bone resorption (158) 158
rats, wistar (157) 157
osteoblasts - drug effects (154) 154
phosphonates (154) 154
rheumatology (153) 153
risedronate sodium (153) 153
etidronic acid - pharmacology (148) 148
cells, cultured (145) 145
osteoclasts (145) 145
health aspects (144) 144
diphosphonates (142) 142
medicine, research & experimental (142) 142
alendronate - adverse effects (141) 141
turnover (140) 140
alendronic acid (139) 139
denosumab (139) 139
imidazoles - pharmacology (139) 139
parathyroid-hormone (137) 137
diphosphonates - adverse effects (136) 136
apoptosis (134) 134
bone-resorption (132) 132
dosage and administration (132) 132
care and treatment (131) 131
double-blind method (130) 130
teriparatide (128) 128
administration, oral (127) 127
femur - drug effects (125) 125
bone resorption - drug therapy (124) 124
cells (123) 123
fractures, bone - prevention & control (123) 123
pamidronate (121) 121
lumbar vertebrae - drug effects (120) 120
randomized-trial (118) 118
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2642) 2642
Japanese (23) 23
Chinese (11) 11
Portuguese (8) 8
French (6) 6
German (6) 6
Spanish (6) 6
Polish (5) 5
Italian (4) 4
Russian (3) 3
Turkish (3) 3
Hungarian (1) 1
Norwegian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 9/2014, Volume 111, Issue 35, pp. 12847 - 12852
Journal Article
Molecules, ISSN 1420-3049, 01/2017, Volume 22, Issue 1, pp. 114 - 114
The potential role of non-antibiotic medicinal products in the treatment of multidrug-resistant Gram-negative bacteria has recently been investigated. It is... 
Drugs | Efflux | Efflux pump inhibitor | MDR | Non-antibiotics | Gram-negative bacteria | Medicinal products | PA βN | Quinolones | medicinal products | INFECTIONS | non-antibiotics | drugs | ESCHERICHIA-COLI | CHEMISTRY, ORGANIC | PREVALENCE | efflux | ACINETOBACTER-BAUMANNII | efflux pump inhibitor | ANTIBACTERIAL ACTIVITY | PSEUDOMONAS-AERUGINOSA | quinolones | ARG-BETA-NAPHTHYLAMIDE | DRUG EFFLUX | PAN | MULTIDRUG-RESISTANCE | ANTIMICROBIAL ACTIVITY | Klebsiella pneumoniae - drug effects | Magnesium Sulfate - pharmacology | Ticlopidine - pharmacology | Atorvastatin Calcium - pharmacology | Escherichia coli - drug effects | Pseudomonas aeruginosa - growth & development | Quinolones - pharmacology | Nicergoline - pharmacology | Microbial Sensitivity Tests | Pseudomonas aeruginosa - metabolism | Escherichia coli - metabolism | Escherichia coli - growth & development | Genes, MDR - drug effects | Klebsiella pneumoniae - metabolism | Salmonella - metabolism | Dipeptides - pharmacology | Acyclovir - pharmacology | Salmonella - drug effects | Pseudomonas aeruginosa - drug effects | Alendronate - pharmacology | Klebsiella pneumoniae - growth & development | Salmonella - growth & development | Anti-Bacterial Agents - pharmacology | Famotidine - pharmacology | Amitriptyline - pharmacology | Drug Resistance, Multiple, Bacterial - genetics | Drug Resistance, Multiple, Bacterial - drug effects | Drug Combinations | Antibiotics | Multidrug resistance | PAβN
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2016, Volume 39, Issue 5, pp. 770 - 777
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 1999, Volume 104, Issue 10, pp. 1363 - 1374
Glucocorticoid-induced osteoporosis may be due, in part, to increased apoptosis of osteocytes and osteoblasts, and bisphosphonates (BPs) are effective in the... 
INDUCED OSTEOPOROSIS | MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATED PROTEIN-KINASE | RESORPTION | IN-VIVO | HUMAN-BONE-MARROW | PARATHYROID-HORMONE | MEDIATED APOPTOSIS | CELL-LINE | ALENDRONATE | MURINE
Journal Article
Digestive Diseases and Sciences, ISSN 0163-2116, 11/2016, Volume 61, Issue 11, pp. 3176 - 3189
Alendronate is an inhibitor of osteoclast-mediated bone resorption, but its clinical utility is limited due to gastrointestinal complications including... 
Biochemistry, general | Hydrogen sulfide | Gastroprotection | Hypoxia-inducible factor-1α | Medicine & Public Health | Alendronate | Hepatology | Gastroenterology | Oncology | Gastric blood flow | Carbon monoxide | Transplant Surgery | PHYSIOLOGY | NITROGEN-CONTAINING BISPHOSPHONATE | INDUCIBLE FACTOR-I | LIPID-PEROXIDATION | MECHANISM | RAT | Hypoxia-inducible factor-1 alpha | NITRIC-OXIDE SYNTHASE | HYPOXIA | DAMAGE | ISCHEMIA-REPERFUSION INJURY | GASTROENTEROLOGY & HEPATOLOGY | Hypoxia-Inducible Factor 1, alpha Subunit - drug effects | Interleukin-1beta - drug effects | Superoxide Dismutase - genetics | Rats, Wistar | Gastric Mucosa - pathology | Male | Interleukin-1beta - genetics | Gastric Mucosa - metabolism | RNA, Messenger - metabolism | Gasotransmitters - pharmacology | Carbon Monoxide - pharmacology | Cyclooxygenase 2 - genetics | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Protective Agents - pharmacology | Gastric Mucosa - drug effects | Glutathione Peroxidase - drug effects | Heme Oxygenase (Decyclizing) - drug effects | Heme Oxygenase (Decyclizing) - genetics | Real-Time Polymerase Chain Reaction | RNA, Messenger - drug effects | Sulfides - pharmacology | Hydrogen Sulfide - pharmacology | Vasodilator Agents - pharmacology | Hypoxia-Inducible Factor 1, alpha Subunit - genetics | Nitric Oxide Synthase Type II - drug effects | Rats | Cyclooxygenase 2 - drug effects | Superoxide Dismutase - drug effects | Blotting, Western | Glutathione Peroxidase - genetics | Bone Density Conservation Agents - pharmacology | Animals | NF-kappa B - genetics | Nitric Oxide Synthase Type II - genetics | Alendronate - pharmacology | Stress, Psychological | Organometallic Compounds - pharmacology | NF-kappa B - drug effects | Vasodilators | Analysis | Gastrointestinal diseases
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2009, Volume 361, Issue 8, pp. 745 - 755
Men receiving androgen-deprivation therapy for nonmetastatic prostate cancer are at high risk for bone loss and fractures. This placebo-controlled study... 
ZOLEDRONIC ACID | MEDICINE, GENERAL & INTERNAL | PLACEBO | BONE-MINERAL DENSITY | FRACTURES | RISK | COMPLICATIONS | RANDOMIZED CONTROLLED-TRIAL | POSTMENOPAUSAL WOMEN | OSTEOPOROSIS | ALENDRONATE | Lumbar Vertebrae - injuries | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Male | Osteoporosis - drug therapy | Prostatic Neoplasms - physiopathology | Bone Remodeling - drug effects | Incidence | Antibodies, Monoclonal, Humanized | Spinal Fractures - prevention & control | RANK Ligand - pharmacology | Injections, Subcutaneous | Aged, 80 and over | RANK Ligand - therapeutic use | Gonadotropin-Releasing Hormone - agonists | Lumbar Vertebrae - physiology | Prostatic Neoplasms - drug therapy | RANK Ligand - adverse effects | Osteoporosis - chemically induced | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Prostatic Neoplasms - surgery | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Lumbar Vertebrae - drug effects | Denosumab | Bone Density Conservation Agents - pharmacology | Orchiectomy | Bone Density - drug effects | Androgen Antagonists - therapeutic use | Aged | Androgen Antagonists - adverse effects | Fractures, Bone - prevention & control | Osteoporosis | Bone density | Prostate cancer | Older people | Men | Index Medicus | Abridged Index Medicus
Journal Article
Osteoporosis International, ISSN 0937-941X, 1/2012, Volume 23, Issue 1, pp. 305 - 315
Strontium ranelate appears to influence more than alendronate distal tibia bone microstructure as assessed by high-resolution peripheral quantitative computed... 
Osteoporosis | Medicine & Public Health | Alendronate | Orthopedics | Gynecology | Rheumatology | Finite elements analysis | Strontium ranelate | HR-pQCT | Microstructure | Endocrinology | HRpQCT | CORTICAL BONE | ELASTIC PROPERTIES | STRENGTH | QUANTITATIVE COMPUTED-TOMOGRAPHY | TRABECULAR BONE | VERTEBRAL FRACTURES | DISTAL RADIUS | ENDOCRINOLOGY & METABOLISM | ARCHITECTURE | PARATHYROID-HORMONE | POSTMENOPAUSAL WOMEN | Bone and Bones - pathology | Thiophenes - therapeutic use | Radius - pathology | Humans | Middle Aged | Osteoporosis, Postmenopausal - pathology | Tomography, X-Ray Computed | Tibia - pathology | Alendronate - therapeutic use | Bone and Bones - drug effects | Bone and Bones - diagnostic imaging | Osteoporosis, Postmenopausal - diagnostic imaging | Radius - drug effects | Organometallic Compounds - therapeutic use | Female | Finite Element Analysis | Lumbar Vertebrae - physiopathology | Double-Blind Method | Tibia - diagnostic imaging | Bone Density Conservation Agents - therapeutic use | Thiophenes - pharmacology | Tibia - drug effects | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Bone Density - drug effects | Alendronate - pharmacology | Femur Neck - physiopathology | Osteoporosis, Postmenopausal - physiopathology | Aged | Organometallic Compounds - pharmacology | Radius - diagnostic imaging | Structure | Bones | Analysis | Dual energy X-ray absorptiometry | Radius | Transformation | Bone turnover | Bisphosphonates | Stress | Post-menopause | Strontium | Alendronic acid | Fractures | Computed tomography | Tibia | Risk assessment | Bone mineral density | Bone strength | Age
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/2014, Volume 111, Issue 28, pp. 10287 - 10292
Bone is a favorable microenvironment for tumor growth and a frequent destination for metastatic cancer cells. Targeting cancers within the bone marrow remains... 
Nanoparticles | Femur | Emulsions | Antineoplastics | Multiple myeloma | Fluorescence | Bones | Pretreatment | Polymers | Cancer | Alendronate-PLGA-PEG | Targeting nanomedicine | Bisphosphonate | Bone metastasis | MULTIPLE-MYELOMA | CELLS | DEXAMETHASONE | ACTIVATION | bone metastasis | VIVO | MULTIDISCIPLINARY SCIENCES | BORTEZOMIB | ANTITUMOR-ACTIVITY | targeting nanomedicine | IN-VITRO | THERAPY | PATHWAY | alendronate-PLGA-PEG | bisphosphonate | Neoplasm Transplantation | Polyglycolic Acid - chemical synthesis | Nanoparticles - chemistry | Humans | Polyglycolic Acid - pharmacology | Polyethylene Glycols - chemistry | Boronic Acids - chemistry | Bone Neoplasms - pathology | Alendronate - chemistry | Bone Neoplasms - metabolism | Drug Delivery Systems | Neoplasms, Experimental - pathology | Multiple Myeloma - drug therapy | Heterografts | Antineoplastic Agents - pharmacology | Bone Neoplasms - drug therapy | Lactic Acid - pharmacology | Tumor Microenvironment - drug effects | Bortezomib | Lactic Acid - chemistry | Nanoparticles - ultrastructure | Polyethylene Glycols - pharmacokinetics | Antineoplastic Agents - chemistry | Multiple Myeloma - metabolism | Xenograft Model Antitumor Assays | Pyrazines - chemistry | Multiple Myeloma - pathology | Animals | Mice, Nude | Polyglycolic Acid - chemistry | Cell Line, Tumor | Mice | Mice, Inbred BALB C | Polyethylene Glycols - chemical synthesis | Lactic Acid - chemical synthesis | Neoplasms, Experimental - metabolism | Pyrazines - pharmacology | Neoplasms, Experimental - drug therapy | Boronic Acids - pharmacology | Index Medicus | Biological Sciences | Physical Sciences
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 06/2019, Volume 85, Issue 6, pp. 1072 - 1083
Journal Article